AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

Amgen · Project update · November 11, 2026

Amgen shared positive results from its Phase 3 clinical trial evaluating dazodalibep for the treatment of Sjögren's disease. The study met its primary endpoints, demonstrating the potential of the therapeutic candidate.

Read the announcement

AntSpace’s summary of Amgen’s own announcement: read the original.

More updates from Amgen